CTIS2023-504986-22-00进行中(未招募)1 期
inezolid or vancomycin surgical site infection prophylaxisLOVip
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 入组人数
- 1,160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+(—)
- 性别
- All
入选标准
- •Adult (=18 years) patients undergoing any elective surgery for which vancomycin is recommended in the guidelines as an alternative to beta-lactams, from different specialties including: neurological, cardiac, orthopedic, vascular, urology, ENT, maxillo-facial or digestive . It is possible to include patients undergoing a re-intervention, if it is not due to a suspected or proven infection., •Known allergy to beta-lactams AND/OR suspected or proven MRSA colonization. Proven MRSA colonization is defined as a positive patient sample within 3 months prior to surgery. Suspected MRSA colonization is defined when the patient has received antibiotic treatment within 3 months prior to surgery or is undergoing re-intervention more than 5 days after the first surgery., •Signed informed consent, •Patient affiliated to a social security system or equivalent.
排除标准
- •Surgery for suspected or proven SSI according to international definitions, •Obesity defined by a body mass index (BMI) >35 kg/m2 or a body weight >100 kg, •Chronic kidney disease defined as glomerular filtration rate (GFR) <60 ml/min per 1.73 m2, •Known allergy to linezolid or vancomycin or one of the excipients in their respective composition, •Hematologic malignancy, •Declared pregnancy or breastfeeding, •Patient under legal protection regime for adults, •Patient already enrolled in LOVip study for a previous surgery, •Patient with limited French proficiency
研究者
相似试验
招募中
4 期
Linezolid or Vancomycin Surgical Site Infection ProphylaxisAntibiotic ProphylaxisGeneral SurgeryNCT05571722Assistance Publique Hopitaux De Marseille1,160
进行中(未招募)
不适用
inezolid vs Vancomycin/Cefazolin in the treatment of hemodialysis patients with catheter-related gram-positive bloodstream infections - N/AEUCTR2004-005159-32-DEPfizer Pharma GmbH332
进行中(未招募)
1 期
inezolid vs Vancomycin/Cefazolin in the treatment of hemodialysis patients with catheter-related gram-positive bloodstream infections - N/ACatheter-related Gram-positive bloodstream infections.MedDRA version: 7.1Level: LLTClassification code 10007810EUCTR2004-005159-32-SKPfizer Limited322
进行中(未招募)
1 期
inezolid vs Vancomycin/Cefazolin in the treatment of hemodialysis patients with catheter-related gram-positive bloodstream infections - N/AEUCTR2004-005159-32-ESPfizer, S.A332
进行中(未招募)
1 期
inezolid vs. Vancomycin/Oxacillin/Dicloxacillin in the Treatment of Catheter-Related Gram Positive Bloodstream Infections. - M/1260/0080EUCTR2004-001511-54-IEPfizer Global Research and Development1,000
